Business Description
SanBio Co Ltd
ISIN : JP3336750009
Description
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.8 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.6 | |||||
| 3-Year EPS without NRI Growth Rate | 25.9 | |||||
| 3-Year FCF Growth Rate | 10.6 | |||||
| 3-Year Book Growth Rate | -36.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 77.62 | |||||
| 6-1 Month Momentum % | 1.32 | |||||
| 12-1 Month Momentum % | -9.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.3 | |||||
| Quick Ratio | 5.3 | |||||
| Cash Ratio | 4.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.5 | |||||
| Shareholder Yield % | 0.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -99.62 | |||||
| ROA % | -48.77 | |||||
| ROIC % | -426.16 | |||||
| 3-Year ROIIC % | -101.46 | |||||
| ROC (Joel Greenblatt) % | -2790.44 | |||||
| ROCE % | -52.08 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 42 | |||||
| Price-to-Tangible-Book | 42.78 | |||||
| EV-to-EBIT | -34.12 | |||||
| EV-to-EBITDA | -34.12 | |||||
| EV-to-FCF | -13.17 | |||||
| Price-to-Net-Current-Asset-Value | 48.13 | |||||
| Price-to-Net-Cash | 64.17 | |||||
| Earnings Yield (Greenblatt) % | -2.93 | |||||
| FCF Yield % | -7.3 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers